CMCSA vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 22, 2026
CMCSA
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | CMCSA | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 5.9844 | 23.0415 | CMCSA |
| PEG Ratio | 2.39 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -1.2% | 2.1% | MRNA |
| Earnings Growth | -66.8% | -85.1% | CMCSA |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 50.5/100 | 49.9/100 | CMCSA |
| Profit Margin | 9.0% | -141.4% | CMCSA |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
CMCSA
NeutralMixed signals - no dominant trend phase, RSI 29
MRNA
MarkupPrice above SMA50, rising 50-day trend (47.8% over 20 days), RSI 72
Fundamentals Snapshot
| Metric | CMCSA | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 6.3 | -38.1 |
| Trailing P/E | 7.3 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.7% | -0.7% |
| Operating Margin | 0.2% | -5.6% |
| EPS | 3.12 | -7.98 |
| Dividend Yield | 0.06% | — |